The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

Due to an ongoing investigation of serious adverse events, it is recommended that the use of Ixchiq ® (chikungunya ... for Disease Control and Prevention (CDC). According to the Agencies, as ...

May 12 (UPI) --U.S. health officials are advising patients using the drug Ixchiq to hold off while authorities ... was initiated Friday by the FDA and CDC while the two federal agencies ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events. Two ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two related deaths, according to the FDA and CDC.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who received the Ixchiq chikungunya vaccine. The FDA and the Centers for Disease ...

Chikungunya is a mosquito-borne tropical disease that causes intense joint pain and fever. Although it is rare in the U.S., about 100 to 200 cases are reported annually, mostly among Americans ...

The FDA and the Centers for Disease Control and Prevention (CDC) are recommending a pause in the use of the single-dose shot, dubbed Ixchiq, in U.S. individuals age 60 and older as investigations ...

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) issued advisories late last week regarding the vaccine Ixchiq, developed by Valneva. Chikungunya is ...

As highlighted by FDA/CDC, adverse events may not be causally related to vaccination, yet thorough evaluation of these cases is critical to ensure the safe use of IXCHIQ ®, of which over 40,000 ...